Efficacy of predicting thrombotic events with combination of dual point-of-care testing (poct) after drug-eluting stent implantation for coronary heart disease: Results from the CILON-T randomized trial POCT substudy

Journal of Atherosclerosis and Thrombosis

Volumn 18, Issue 10, 2011, Pages 914-923

  Lee, Seung Pyo ^a   Park, Kyung Woo ^a   Shin, Dong Ho ^a   Lee, Hae Young ^a   Kang, Hyun Jae ^a   Koo, Bon Kwon ^a   Suh, Jung Won ^b   Youn, Tae Jin ^b   Choi, Dong Ju ^b   Chae, In Ho ^b   Kim, Hyo Soo ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Aspirin; Clopidogrel; Platelet function test; Point of care systems; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; POST HOC ANALYSIS; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SMOKING; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; CORONARY DISEASE; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POINT-OF-CARE SYSTEMS; PROSPECTIVE STUDIES; THROMBOSIS;

EID: 80055118794     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.9290     Document Type: Article

References (30)

1. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF: Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation, 2009; 119: 237-242.
2. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS: Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J, 2008; 29: 992-1000.
3. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA: Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol, 2007; 49: 657-666.
4. Park KW, Park JJ, Jeon KH, Kang SH, Oh IY, Yang HM, Cho HJ, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS: Clinical Predictors of High Posttreatment Platelet Reactivity to Clopidogrel in Koreans. Cardiovasc Ther, 2010.
5. Park KW, Park JJ, Lee SP, Oh IY, Suh JW, Yang HM, Lee HY, Kang HJ, Cho YS, Koo BK, Youn TJ, Chae IH, Choi DJ, Oh BH, Park YB, Kim HS: Cilostazol Attenuates On-Treatment Platelet Reactivity in Patients with CYP2C19 Loss of Function Alleles Receiving Dual Anti-platelet Therapy: a Genetic Substudy of the CILON-T Randomized Controlled Trial. Heart, 2011; 97: 641-647.
6. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation, 2004; 109: 3171-3175.
7. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G: Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol, 2008; 52: 1128-1133.
8. Ben-Dor I, Kleiman NS, Lev E: Assessment, mechanisms, and clinical implication of variability in platelet response Combination of Point-of-Care Assays to aspirin and clopidogrel therapy. Am J Cardiol, 2009; 104: 227-233.
9. Chen WH, Cheng X, Lee PY, Ng W, Kwok JY, Tse HF, Lau CP: Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med, 2007; 120: 631-635.
10. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM: Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA, 2010; 303: 754-762.
11. Gori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, Paniccia R, Buonamici P, Gensini GF, Vergara R, Abbate R, Antoniucci D: Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol, 2008; 52: 734-739.
12. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, Bray PF, Kleiman NS: Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol, 2006; 47: 27-33.
13. Lee SP, Suh JW, Park KW, Lee, KY, Kang HJ, Koo BK, Chae IH, Choi DJ, Rha SW, Bae JW, Cho MC, Kwon TG, Bae JH, Kim HS; CILTON-T Investigators: Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet theraphy on ischemic complication after drug-eluting stent implantation (CILTON-T)' study: A multicenter randomized trial evaluating the efficacy of ilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease. Trials, 2010; 11: 87.
14. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, Cho YS, Youn TJ, Chae IH, Choi DJ, Rha SW, Bae JH, Kwon TG, Bae JW, Cho MC, Kim HS: Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: Results of CILON-T (Influence of CILostazol-based triple antiplatelet therapy ON Ischemic Complication after drug-eluting stenT implantation) Trial. J Am Coll Cardiol, 2011; 57: 280-289.
15. Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antoniucci D, Gensini GF, Abbate R, Prisco D: Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost, 2007; 5: 1839-1847.
16. Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V: Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol, 2006; 28: 315-322.
17. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michel-son AD: Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol, 2007; 50: 1822-1834.
18. Chen WH, Lee PY, Ng W, Tse HF, Lau CP: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol, 2004; 43: 1122-1126.
19. Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS: Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol, 2009; 103: 1339-1343.
20. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO; 2005 WRITING COMMITTEE MEMBERS, Feldman TE, Kern MJ, O'Neill WW, Schaff HV, Whitlow PL, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW: 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation, 2008; 117: 261-295.
21. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Buttner HJ, Neumann FJ: Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol, 2006; 48: 1742-1750.
22. Geisler T, Zurn C, Simonenko R, Rapin M, Kraibooj H, Kilias A, Bigalke B, Stellos K, Schwab M, May AE, Herdeg C, Gawaz M: Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J, 2010; 31: 59-66.
23. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US: Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol, 2005; 46: 1820-1826.
24. Marroquin OC, Kip KE, Kelley DE, Johnson BD, Shaw LJ, Bairey Merz CN, Sharaf BL, Pepine CJ, Sopko G, Reis SE; Women's Ischemia Syndrome Evaluation Investigators: Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation, 2004; 109: 714-721.
25. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, Togni M, Wenaweser P, Billinger M, Seiler C, Gay S, Meier B, Pichler WJ, Jüni P, Virmani R, Windecker S: Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation, 2009; 120: 391-399.
26. Windecker S, Meier B: Late coronary stent thrombosis. Circulation, 2007; 116: 1952-1965.
27. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD: Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation, 2004; 109: 701-705.
28. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR: Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ, 2008; 336: 195-198.
29. Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L, Bonizzoni E, Carlino M, Gerckens U, Godino C, Melzi G, Michev I, Montorfano M, Sangiorgi GM, Qasim A, Chieffo A, Briguori C, Grube E: Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation, 2007; 116: 745-754.
30. Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, Cheong SS, Kim JJ, Park SW, Park SJ: Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. JACC Cardiovasc Interv, 2008; 1: 494-503.